CS20AT04 / CoreStem - LARVOL DELTA

Long-term Follow-up for Evaluating the Safety of CS20AT04 in Subject With Lupus Nephritis (clinicaltrials.gov) - P=N/A | N=6 | Completed | Sponsor: Corestemchemon, Inc. | Active, not recruiting ➔ Completed

Trial completion • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology

Long-term Follow-up for Evaluating the Safety of CS20AT04 in Subject With Lupus Nephritis (clinicaltrials.gov) - P=N/A | N=7 | Active, not recruiting | Sponsor: Corestemchemon, Inc. | Trial completion date: Jan 2024 ➔ May 2024

Trial completion date • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology

Safety and tolerability of bone marrow-derived mesenchymal stem cells in lupus animal models and a phase I clinical trial in humans. (PubMed, Lupus) - P1 | "We defined the characteristics of BM-MSCs and identified their safety and tolerability in both animal models and a phase I clinical trial. The maximum tolerated dose was determined to be 3.0×10 cells/kg in patients with LN."

Journal • P1 data • Preclinical • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Musculoskeletal Pain • Nephrology • Oncology • Systemic Lupus Erythematosus • Transplantation

Exploring the Efficacy and Safety of CS20AT04 (Allogenic Bone Marrow-Derived Stem Cell) in Systemic Lupus Erythematosus Patients (clinicaltrials.gov) - P2; N=10; Recruiting; Sponsor: Hanyang University Seoul Hospital

New P2 trial • Complement-mediated Rare Disorders • Glomerulonephritis • Hematological Disorders • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Systemic Lupus Erythematosus

Long-term Follow-up for Evaluating the Safety of CS20AT04 in Subject With Lupus Nephritis (clinicaltrials.gov) - P; N=7; Recruiting; Sponsor: Corestem, Inc.

Clinical • New trial • Complement-mediated Rare Disorders • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis

Long-term Follow-up for Evaluating the Safety of CS20AT04 in Subject With Lupus Nephritis (clinicaltrials.gov) - P=N/A; N=7; Active, not recruiting; Sponsor: Corestem, Inc.; Recruiting ➔ Active, not recruiting

Enrollment closed • Complement-mediated Rare Disorders • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis

[VIRTUAL] SAFETY OF CS20AT04, A HAPLOIDENTICAL ALLOGENEIC BONE MARROW-DERIVED MESENCHYMAL STEM CELLS, IN A PHASE 1 STUDY IN LUPUS NEPHRITIS (EULAR 2020) - P1 | "CS20AT04 was well tolerated in single dose up to 3.0 x 106 cells/kg in patients with lupus nephritis."

Clinical • P1 data • Complement-mediated Rare Disorders • Immune Modulation • Immunology • Inflammation • Lupus • Lupus Nephritis

Evaluate the Safety of CS20AT04 Inj. in Subjects With Lupus Nephritis (clinicaltrials.gov) - P1; N=7; Completed; Sponsor: Corestem, Inc.; Trial completion date: Jul 2018 ➔ Aug 2019; Enrolling by invitation ➔ Completed; Trial primary completion date: Jun 2018 ➔ Mar 2019

Trial completion • Trial completion date • Trial primary completion date